ABSTRACT

Gastric cancer (GC) is associated with high morbidity and mortality rates. Thus, early diagnosis is important to improve disease prognosis. Endoscopic assessment represents the most reliable imaging method for GC diagnosis; however, it is semi-invasive and costly and heavily depends on the skills of the endoscopist, which limit its clinical applicability. Therefore, the search for new sensitive biomarkers for the early detection of GC using noninvasive sampling collection methods has attracted much attention among scientists. Urine is considered an ideal biofluid, as it is readily accessible, less complex, and relatively stable than plasma and serum. Over the years, substantial progress has been made in screening for potential urinary biomarkers for GC. This review explores the possible applications and limitations of urinary biomarkers in GC detection and diagnosis.

Keywords: Gastric cancer; Diagnostic; Noninvasive detection; Urinary biomarkers

INTRODUCTION

Gastric cancer (GC) is a malignant tumor originating from the gastric mucosa and associated with high morbidity and mortality [1,2]. Surgical resection is still considered the best treatment approach for GC. However, patients with early-stage cancer are often asymptomatic and thus lose their chance to undergo surgery. Therefore, early diagnosis is crucial for improving clinical outcomes and prognosis [3,4]. Endoscopic assessment is the most reliable imaging method for GC diagnosis, which allows clinicians to collect tissue biopsy and perform endoscopic ultrasound to determine the depth of invasion (tumor or T stage). However, it is semi-invasive and costly and heavily depends on the skills of the endoscopist, which limits its clinical applicability [5]. Other common diagnostic approaches include magnetic resonance imaging, X-ray pepsinogen I, and X-ray pepsinogen II. These approaches offer lower sensitivity and specificity and are costly. Thus, the search for novel noninvasive biomarkers, especially for early-stage GC, has become a hot topic among scientists.

Urine, an ideal biofluid, has gained increasing attention in biomarker discovery. Urine is a highly desirable biospecimen for biomarker analysis; it can be easily obtained when compared with plasma and serum [6,7]. The application of urinary biomarkers in tumors...
Urinary Biomarkers for Gastric Cancer

Yan Lu
https://orcid.org/0000-0001-6610-7212

Funding
This work was funded by the Research Projects of Gansu Provincial Hospital (Grant No. 21GSSYB-38 and No. 21GSSYC-43).

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Author Contributions
Conceptualization: W.L.; Data curation: Y.L., 1Y.X.; Formal analysis: Y.L., 2Y.X.; Validation: L.D., Y.Y., 3Y.X.; Visualization: L.F.; Writing - original draft: L.D.; Writing - review & editing: L.Y.
1Y.X., Xiumei Yuan; 2Y.X., Xingwen Yang; 3Y.X., Xiaoyan Yang.

DETECTION TECHNIQUES OF BIOMARKERS IN THE URINE

Continuous improvements in urine testing technologies have enabled the identification of many substances in urine, especially low-abundance substances, thus further promoting the discovery of new biomarkers. Over the last two decades, urine RNomics, proteomics, and metabolomics have developed rapidly in parallel with advanced omics and medical tests [11]. Microarray technologies, quantitative real-time polymerase chain reaction (PCR), and next-generation RNA sequencing have prompted the discovery of many urinary microRNAs (miRNAs) in cancer [12]. Additionally, breakthroughs in analytical technologies have supported metabolic profiling, making it one of the most rapidly expanding disciplines in cancer research. Significant progress has been made in acquiring metabolomic data, sampling techniques, experimental techniques, and data characterization [13,14]. Furthermore, urinary metabolomics has been advanced by recent technological developments in mass spectrometry (MS), nuclear magnetic resonance (NMR), gas and liquid chromatography (LC), and capillary electrophoresis (CE), thus improving reproducibility and metabolome coverage [15]. Meanwhile, there are several different techniques for proteomic studies, including tandem MS (MS/MS), LC-MS, CE-MS, surface-enhanced laser desorption ionization MS, and array technology have been implemented for proteomics analysis of urine and biomarker discovery [16]. Fig. 1 summarizes the applications of urine detection technologies for GC urinary biomarker research.

MICRORNAS IN URINE

miRNAs are a class of 21–28 nucleotide noncoding RNAs that mediate gene expression post-transcriptionally and are involved in carcinogenesis [17,18]. To date, a number of miRNAs have been discovered, some of which are candidate biomarkers for early diagnosis [19] and are highly stable in tissues and body fluids, including urine [20]. Moreover, studies have shown that urinary miRNAs remained unchanged even after seven cycles of freezing and thawing or incubation at room temperature for 72 hours [21]. Various technologies such as microarray, quantitative real-time PCR, and next-generation RNA sequencing have been widely used to analyze miRNA expression profiles in both biofluids and tissues [22-24]. Iwasaki et al. demonstrated higher levels of miR-6807-5p and miR-6856-5p in the urine of patients with GC than in control subjects. A combination of miR-6807-5p and miR-6856-5p achieved an area under the curve (AUC) of 0.748, suggesting that these miRNAs could be used to diagnose early-stage GC [25]. Another study showed that urinary miR-376c was also significantly increased in 20 patients with GC when compared with that of 11 healthy individuals, and it displayed 64% specificity and 60% sensitivity, with an AUC of 0.70.
Moreover, Kao et al. [27] performed a quantitative stem-loop PCR assay of miR-21-5p urinary samples from healthy individuals, preoperative patients, and postoperative patients with GC. Compared with healthy controls, patients with GC had significantly upregulated miR-21-5p, and urinary miR-21-5p levels showed a clear downward trend after tumor tissue resection. Interestingly, another study reported no urinary miR-21-5p in patients with GC and healthy controls [25]. The different results may be explained as follows: 1) The sample sizes were different and could significantly affect the results. Therefore, large-scale multicenter studies are warranted to validate these biomarkers. 2) Cancer biomarkers vary across stages of disease progression, and studies involving patients at different stages may report different results. 3) GC is a multifactorial disease, and environmental and genetic factors may affect its etiology. There are differences in the incidence of GC among different regions and races. Whether or not biomarkers reflect disease status across diverse ethnic groups remains unknown. 4) Biomarkers may exhibit different expression levels in different subtypes.

In summary, all these data suggest that miRNA in urine may be a promising noninvasive diagnostic biomarker of the disease; however, their significance needs to be validated in further independent large-scale cohorts.

**Table 1** summarizes the literature on urinary miRNAs in GC, focusing on the main aspects of the studies presented (i.e., study design, biological function, and results).

---

**DNA AND RNA OXIDATIVe DAMAGE MARKERS IN URINE**

Nucleic acids are continuously oxidized in the cell [28], and oxidative modifications of nucleic acids are associated with various diseases including cancer [29]. Oxidized nucleosides
are fairly water-soluble, are generally excreted into the urine, and do not undergo further metabolism [30]. 8-Oxo-7,8-dihydroguanine (8-oxoGua) and 8-hydroxyguanosine (8-OHG) are typical markers of oxidative modification of RNA, while 8-oxo-7′-deoxyguanosine (8-oxodG) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) are markers of oxidative modification of DNA. Their urinary concentrations reflect the mean rate of oxidatively generated modifications of RNA and DNA in organism [31].

Roszkowski et al. [29] investigated the daily urinary excretion of 8-oxoGua and 8-oxodG in a large cohort of 222 patients with malignant cancer, including gastrointestinal cancer, and found that the urinary levels of 8-oxoGua and 8-oxodG were significantly higher in the GC group than in healthy control group. Furthermore, Borrego et al. [32] confirmed that urinary 8-oxo-2′-deoxyguanosine (8-oxodG) levels were significantly elevated in patients with GC and progressively declined after gastrectomy. The latest research successfully quantified 8-OHdG and 8-OHG in urine using robust solid-phase extraction (SPE) combined with ultra-performance LC-MS/MS in 70 healthy individuals and 60 patients with GC and found that the concentrations of urinary 8-OHdG and 8-OHG were increased dramatically in patients with GC, with AUC of 0.777 and 0.841, respectively [33].

Table 2 summarizes urinary DNA and RNA oxidative damage markers for GC.

### Table 2. Summary of potential DNA and RNA oxidative damage markers for the early diagnosis of gastric cancer

| Type | Biomarker | Study design | Biological function | AUC | Sensitivity/Specificity | Study |
|------|-----------|--------------|---------------------|-----|------------------------|-------|
| RNA  | 8-oxoGua  | Case control design: 11 gastrointestinal cancer cases and 85 healthy controls | Upregulated in GC; correlated with oxidative stress situation | -   | -                      | Roszkowski et al. [29] |
| RNA  | 8-OHG     | Case control design: 60 GC cases and 70 healthy controls | Upregulated in GC; correlated with occurrence and development | 0.841 | -                      | Chen et al. [33] |
| DNA  | 8-oxodG   | Case control design: 11 cases of gastrointestinal cancer and 85 healthy controls; Case control design: 48 preoperative cases of GC, 48 postoperative cases, and 48 healthy controls | Upregulated in GC; correlated with oxidative stress situation | -   | -                      | Roszkowski et al. [29] |
| DNA  | 8-OHdG    | Case control design: 60 GC cases and 70 healthy controls | Upregulated in GC; correlated with occurrence and development | 0.777 | -                      | Chen et al. [33] |

**ENDOGENOUS METABOLITES IN URINE**

Metabolites are small substrates and products of metabolism with mass units below 2000 that drive essential cellular functions [34]. Metabolites represent the integrated outputs of the genome, transcriptome, and proteome. Moreover, they reflect the upstream input from various external factors, including the environment, diet, lifestyle, and drug exposure.

---

**Table 1. Summary of potential urinary miRNAs for the early diagnosis of gastric cancer**

| Type      | Biomarker                  | Study design                                                                 | Biological function                                                                 | AUC  | Sensitivity/Specificity | Study                      |
|-----------|----------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------|-------------------------|----------------------------|
| miRNA     | miR-6807-5p/miR-6856-5p    | Case control design: training cohort: 95 GC cases, 95 healthy controls; validation cohort: 54 GC cases, 54 healthy controls | Upregulated in GC; correlated with H. pylori status                                  | GC: 0.885 | GC: 76.9%/88.9%      | Iwasaki et al. [25]        |
|          | H. pylori+                 |                                                                              | -                                                                                   | 0.748 | Stage I GC, Stage II GC |                           |
| miRNA     | miR-376c                  | Case control design: 20 GC cases and 11 healthy controls                      | Upregulated in GC; correlated with proliferation, migration, and anchorage-independent growth | 0.70  | 60%/64%                 | Hung et al. [26]           |
| miRNA     | miR-21-5p                 | Case control design: 50 GC cases and healthy controls                        | Upregulated in GC; correlated with disease status                                   | -    | -                      | Kao et al. [27]            |

miRNA = microRNA; AUC = area under the curve; H. pylori = Helicobacter pylori; GC = gastric cancer; - = no data available.
Metabolic alterations can be used to detect variations in the biology and morphology of cancers to guide clinical management decisions [15]. Urine is commonly used for profiling metabolic and screening clinical biomarkers [36,37]. To date, various endogenous metabolites involved in multiple metabolic pathways have been detected in urine (Fig. 2). For example, metabolomics has been used to analyze urine for GC biomarkers [38]. GC’s distinct urinary metabolomic profile identification of GC could provide an efficient, non-invasive diagnostic modality.

Several studies have examined urinary metabolites for GC detection. Amino acids, bile acids, and oxidative nucleic acid metabolites may be used as diagnostic biomarkers for GC. A previous study analyzed metabolites in 293 urine samples by gas chromatography coupled to mass spectrometry (GC-MS) and found that the urine levels of 10 amino acids (namely, valine, alanine, proline, tryptophan, isoleucine, serine, threonine, tyrosine, methionine, and glycine) were significantly higher in patients with GC and showed diagnostic ability with an AUC from 0.693 to 0.823 [39]. Moreover, Chan et al. detected increased urinary alanine concentrations in patients with GC when compared with those in healthy individuals. They also established a diagnostic model using alanine, 2-hydroxyisobutyrate (2-HIB), and 3-indoxylsulfate (3-IS) for GC, with an AUC of corresponding receiver operating characteristic curve of 0.95, specificity of 80%, and sensitivity of 95% for predicting GC [40]. A study comparing the concentrations of 44 metabolites in the urine of 50 patients with GC and 50 healthy individuals revealed that alanine, tyrosine, glycolate, glycine, methionine, phenylalanine, and arginine levels were significantly increased in patients with GC; moreover, the combination of alanine, acetate, 4-hydroxyphenylacetate, and phenylacetyl glycine showed high sensitivity and specificity (sensitivity: 86%, specificity: 92%) for GC prediction [41]. A further CE-MS metabolomics study found increased lactic acid, valine, leucine, arginine, and isoleucine levels in patients with GC when compared with control subjects. However, histidine, aspartate, citric acid, succinate, malic acid, methionine, and serine were markedly decreased in patients with GC [42]. Kwon et al. [43] employed NMR metabolomics to urine samples to compare urinary metabolites in 103 patients with GC and 100 age- and sex-matched healthy control subjects. In this study, the population included more patients with stage I disease (66.99%). They found that phenylalanine, alanine, creatinine, hippurate, citrate, glycerol, creatine, 3-hydroxybutyrate, and taurine were

Fig. 2. Common endogenous metabolites in urine.
significantly different between healthy individuals and patients with GC, with AUCs ranging from 0.632 to 0.936. Furthermore, the early-stage GC diagnostic model exhibited a specificity of 97% and a sensitivity of 94.7%. They also found that urinary metabolomics had a higher diagnostic value than CEA, CA19-9, and CA72-4 levels. A more recent study demonstrated that the levels of D-serine (D-Ser) and D-isoleucine (D-Ile) were significantly higher in the GC group than in the healthy group, while the levels of β-(pyrazol-1-yl)-L-alanine (L-PA) in the GC group were lower than those in the HC group. Univariable analysis of age, L-PA, D-Ser, and D-Ile showed that their AUC values ranged from 0.760 to 0.895, while multivariate model analysis showed that the AUC of the combined indicators was 0.977, showing great potential in diagnosing GC [38].

Lyu et al. [44] used an SPE column that contains a covalent organic framework material coupled to LC-MS/MS to quantitatively analyze samples from patients with GC and healthy control subjects. They found that the levels of hyodeoxycholic acid, cholic acid, and chenodeoxycholic acid were significantly higher in patients with GC, while the glycochenodeoxycholic acid level in patients with GC was significantly lower than that in control subjects. These bile acids achieved favorable diagnostic performance with AUCs of 0.854, 0.851, 0.753, and 0.769, respectively.

Table 3 summarizes the urinary metabolites used for GC detection.

### EXTRACELLULAR VESICLES (EVs) AND EXOSOMES IN URINE

EVs are nano-sized membrane vesicles containing nucleic acids, lipids, and proteins, which play important roles in intercellular communication by transferring their components to

| Type | Biomarker | Study design | Biological function | AUC | Sensitivity/Specificity | Study |
|------|-----------|--------------|---------------------|-----|------------------------|-------|
| Metabolites | 10 amino acids (alanine, glycine, valine, isoleucine, serine, threonine, proline, methionine, tyrosine, and tryptophan) | Case control design: 112 GC cases and 87 healthy controls | Upregulated in GC; correlated with occurrence and prognosis | 0.693–0.823 | 62.3%–91.5%/41.4%–78.2% | Chen et al. [39] |
| Metabolites | 2-hydroxyisobutyrate (2-HIB), 3-indoxylsulfate(3-IS), and alanine | Case control design: 43 GC cases, 40 BN controls, and 40 healthy controls | Correlated with establishing diagnostic regression model | 0.95 | 95%/80% | Chan et al. [40] |
| Metabolites | Alanine, acetate, 4-hydroxyphenylacetate, phenylacetylglucose | Case control design: 50 GC cases and 50 healthy controls | Upregulated in GC; correlated with T stage | - | 86%/92% | Jung et al. [41] |
| Metabolites | Methionine, arginine, leucine, serine, aspartate, valine, isoleucine, histidine, succinate, citric acid, malic acid, lactic acid | Case control design: 26 GC cases and 14 healthy controls | 5 metabolites were upregulated in GC and 7 metabolites were downregulated in GC; correlated with disease stage | 1.000 | - | Chen et al. [42] |
| Metabolites | Alanine, citrate, creatine, creatinine, glycerol, hippurate, phenylalanine, tyrosine, and 3-hydroxybutyrate | Case control design: 103 GC cases and 100 healthy controls | 6 metabolites were upregulated in GC and 3 metabolites were downregulated in GC; correlated with disease stage | 0.632–0.936 | 50%–90%/70%–90% | Kwon et al. [43] |
| Metabolites | β-(pyrazol-1-yl)-L-alanine, D-serine, D-isoleucine | Case control design: 84 GC cases and 80 healthy controls | 2 metabolites were upregulated in GC and 1 metabolite was downregulated in GC; correlated with H. pylori status | 0.670–0.889 | - | Huang et al. [38] |
| Metabolites | Hyodeoxycholic acid, cholic acid, glycochenodeoxycholic acid, and chenodeoxycholic acid | Case control design: 76 GC cases and 32 healthy controls | 3 metabolites were upregulated in GC and 1 metabolite was downregulated in GC | 0.753–0.854 | - | Lyu et al. [44] |

AUC = area under the curve; GC = gastric cancer; BN = benign gastric disease; - = no data available.
recipient cells [45]. EVs secreted from cancer cells participate in fibrosis, angiogenesis, metastasis, and evasion of immune surveillance [46,47]. EVs can be found in various body fluids such as plasma, urine, breast milk, saliva, semen, lymphatic fluid, cerebrospinal fluid, sputum, amniotic fluid, and synovial fluid [48]. Urinary EVs appear to be particularly promising for the early diagnosis of GC. A prospective study performed metagenome analysis using body fluid samples (gastric juice, urine, and blood) to examine the distinct microbial composition of bacteria-derived EVs from patients with GC. Among the four sample types of prediction models, the model using urine samples showed the highest AUC of 0.823, with 67.7% sensitivity, 84.9% specificity, and 76.1% accuracy [49].

Exosomes are EVs of 30–150 nm in diameter that are present in almost all body fluids and contain miRNAs, mRNA, IncRNAs, and proteins [50,51]. Exosomes can regulate the expression of target genes, signal pathways, and cell transformation of receptor cells by mediating information transmission between tumor cells and the tumor microenvironment, which have become important mediators of tumorigenesis, tumor growth, angiogenesis, and metastasis [52] and have been identified as prognostic and diagnostic biomarkers for cancer (Fig. 3). Qian et al. [53] applied next-generation sequencing technology to identify exosomal miRNAs in the serum and urine of patients with GC and healthy individuals and found urinary exosomal hsa-miR-1246 upregulation and hsa-miR-139-5p and hsa-miR-345-5p downregulation in GC.

Fig. 3. Exosomes take part in multiple biochemical processes involved in cancer and are present in almost all body fluids. This image was created using BioRender (http://biorender.com/; accessed on June 29, 2020).
PROTEINS IN URINE

Urinary proteins may be used for the early diagnosis of GC. Dong et al. [54] found that the protein expression levels of endothelial lipase (EL) in the GC group were significantly lower than those in the normal groups, and EL was proposed to act as a promising diagnostic marker of GC, because it achieved an AUC of 0.967 and a 95% confidence interval (CI) of (0.942–0.993). A study based on a computational method for the prediction of excretory proteins confirmed that urinary EL was substantially reduced in patients with GC, obtaining an AUC greater than 0.9, with true positive and false positive rates of 85% and 9.5%, respectively [55].

Metalloproteinases, a group of zinc-dependent proteinases, activate a water molecule that performs a nucleophilic attack on the scissile peptide bond [56]. Matrix metalloproteinases (MMPs) belong to the family M10 of metalloproteinases [57], which degrade various proteins in the extracellular matrix and regulate growth factors, cytokines, chemokines, and cytoskeletal proteins [58]. MMPs are involved in a wide range of biological processes such as cellular differentiation, tissue repair, morphogenesis, embryogenesis, cell mobility, angiogenesis, cell proliferation, migration, wound healing, apoptosis, and main reproductive events, such as ovulation and endometrial proliferation [59]. MMPs are recognized as boosters in tumorigenesis [60]. ADAMs (a disintegrin and metalloproteases), a family of MMP related to metalloproteinases, are involved in cell adhesion, cell signaling, and proteolytic processing of numerous transmembrane proteins and play important roles in tumor progression and metastasis [61]. A previous study found increased MMP-9/NGAL (neutrophil gelatinase-associated lipocalin) complex and ADAM12 in the urine of patients with GC compared to healthy control subjects, and a combination of MMP-9/NGAL complex and ADAM12 showed 77.1% sensitivity and 82.9% specificity, with an AUC of 0.825 for the diagnosis of GC [62].

Many proteomics-based biomarkers that rely on single proteins are currently being used for clinical diagnosis. However, because of the lack of specificity of single biomarkers, a step has been made toward identifying and validating panels of biomarkers rather than attempting to identify a unique ideal diagnostic candidate that might not exist [63]. Urinary proteomics used to search for early markers has gained increasing attention because the complexity of the urinary proteome is lower than that of the plasma proteome, making it easier to detect low-abundance protein changes [64]. A proteomics study was used to screen urine diagnostic markers of GC; the study revealed that urinary levels of TFF1 (trefoil factor 1), ADAM12 (a disintegrin and metalloproteinase domain-containing protein 12), PGA3 (pepsinogen 3), and BARD1 (BRCA1-associated RING domain 1) were significantly higher in the GC group than in the healthy control group. Moreover, uTFF1 and uADAM12 appeared to be significant independent proteins for GC diagnosis. In addition, these combination biomarkers displayed an important diagnostic value for GC (AUC of uTFF1+uADAM12 0.815, 95% CI, 0.754–0.877; AUC of uTFF1 + uADAM12+ Helicobacter pylori 0.832, 95% CI, 0.773–0.892). These proteins display sex-specific effects; for male GC, the panel of uTFF1/uADAM12/H. pylori demonstrated good performance with an AUC of 0.858, whereas for female GC, another combination of uTFF1/uBARD1/H. pylori also achieved an AUC of 0.893 [65].

Despite some progress, urinary proteomics research and clinical translation remain in their infancy, as some major problems have not yet been resolved. Specimen collection, processing, and fractionation schemas, as well as analytical platform differences and data
reduction method variables, create barriers to interlaboratory comparisons [66]. Hence, standardization processes and applicable data normalization methods are required. Defining urinary protein levels in healthy individuals remains an important and challenging problem. Age, sex, diet, exercise, diurnal variation, and hormone status contribute to differences in the proteomics of normal urine [67]. Large-scale longitudinal studies of individuals are needed to establish a reference interval for urinary proteomics.

**Table 4** summarizes the urinary proteins used for GC detection.

## FUTURE PERSPECTIVE

Urine is an ideal biofluid for biomarker discovery in GC. Urinary miRNAs, proteins, and metabolites have all been reported as possible biomarkers of GC. The current large research output and financial investment in this area undoubtedly confirm the great expectations for the potential urinary analysis might have. Nevertheless, owing to a lack of robust validation, evidence is insufficient to support their clinical use. Most studies on urinary biomarkers for GC diagnosis have been small-scale. Therefore, further research with a larger sample size is required. Choosing a greater number of patients, including low-prevalence populations and premalignant conditions such as intestinal metaplasia and atrophic gastritis, helps represent the areal screening population. With rapid developments in computer technology and medicine, using artificial intelligence to combine “signals” from multiple patterns will facilitate the process of discovery and verification. In addition, combining different biomarker values, clinical evidence, and biochemical parameters will be a great strategy to increase the diagnostic accuracy.

## REFERENCES

1. Lai S. A human mode of intestinal type gastric carcinoma. Med Hypotheses 2019;123:27-29. [PUBMED](https://doi.org/10.1016/j.mehy.2019.03.042) [CROSSREF](https://www.sciencedirect.com/science/article/pii/S0301462219303201)
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. [PUBMED](https://doi.org/10.3322/caac.21492) [CROSSREF](https://onlinelibrary.wiley.com/doi/10.1002/caac.21492)
3. Jayanthi VS, Das AB, Saxena U. Recent advances in biosensor development for the detection of cancer biomarkers. Biosens Bioelectron 2017;91:15-23. [PUBMED](https://doi.org/10.1016/j.bios.2016.12.058) [CROSSREF](https://www.sciencedirect.com/science/article/pii/S0956566316327794)
4. Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M, et al. The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice. Biomed Pharmacother 2017;95:1082-1090.

5. Chan AW, Gill RS, Schiller D, Sawyer MB. Potential role of metabolomics in diagnosis and surveillance of gastric cancer. World J Gastroenterol 2014;20:12874-12882.

6. Zhang T, Duran V, Vanarsa K, Mohan C. Targeted urine proteomics in lupus nephritis - a meta-analysis. Expert Rev Proteomics 2020;17:767-776.

7. Njoku K, Chiassérini D, Jones ER, Barr CE, O’Flynn H, Whetton AD, et al. Urinary biomarkers and their potential for the non-invasive detection of endometrial cancer. Front Oncol 2020;10:559016.

8. Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol 2013;10:206-218.

9. Dingès SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol 2019;16:339-362.

10. Bax C, Lotesorierie BJ, Sironi S, Capelli L. Review and comparison of cancer biomarker trends in urine as a basis for new diagnostic pathways. Cancers (Basel) 2019;11:1244.

11. Tan J, Qin F, Yuan J. Current applications of artificial intelligence combined with urine detection in disease diagnosis and treatment. Transl Androl Urol 2021;10:1769-1779.

12. Sun IO, Lerman LO. Urinary microRNA in kidney disease: utility and roles. Am J Physiol Renal Physiol 2019;316:F785-F793.

13. Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal 2014;87:1-11.

14. Patel S, Ahmed S. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal 2015;107:63-74.

15. Burton C, Ma Y. Current trends in cancer biomarker discovery using urinary metabolomics: achievements and new challenges. Curr Med Chem 2019;26:5-28.

16. Pejcic M, Stojnev S, Stefanovic V. Urinary proteomics—a tool for biomarker discovery. Ren Fail 2010;32:259-268.

17. Cousijn J. Breakthrough of the year. Small RNAs make big splash. Science 2002;298:2296-2297.

18. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004;32:D109-D111.

19. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-D144.

20. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-1741.

21. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012;41:1871-1878.

22. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004;1:47-53.

23. Biscontin A, Casara S, Cagnin S, Tombolan L, Rosolen A, Lanfranchi G, et al. New miRNA labeling method for bead-based quantification. BMC Mol Biol 2010;11:44.
24. Meng Y, Eirin A, Zhu XY, Tang H, Chanana P, Lerman A, et al. The metabolic syndrome alters the miRNA signature of porcine adipose tissue-derived mesenchymal stem cells. Cytometry A 2018;93:93-103.

25. Iwasaki H, Shimura T, Yamada T, Okuda Y, Natsume M, Kitagawa M, et al. A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol 2019;54:1064-1069.

26. Hung PS, Chen CY, Chen WT, Kuo CY, Fang WL, Huang KH, et al. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. PLoS One 2017;12:e0177346.

27. Kao HW, Pan CY, Lai CH, Wu CW, Fang WL, Huang KH, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget 2017;8:56389-56397.

28. Poulsen HE, Specht E, Broedbaek K, Henriksen T, Ellervik C, Mandrup-Poulsen T, et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med 2012;52:1353-1361.

29. Roszkowski K, Joziwicki W, Błaszczyk P, Mucha-Malecka A, Siomek A. Oxidative damage DNA: 8-oxoGua and 8-oxodG as molecular markers of cancer. Med Sci Monit 2011;17:CR329-333.

30. Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl) 1996;74:297-312.

31. Jørs A, Lund MA, Jepsen T, Hansen T, Poulsen HE, Holm JC. Urinary markers of nucleic acid oxidation increase with age, obesity and insulin resistance in Danish children and adolescents. Free Radic Biol Med 2020;155:81-86.

32. Borrego S, Vazquez A, Dasi F, Cerdá C, Iradi A, Tormos C, et al. Oxidative stress and DNA damage in human gastric carcinoma: 8-oxo-7'-8-dihydro-2'-deoxyguanosine (8-oxo-dG) as a possible tumor marker. Int J Mol Sci 2013;14:3467-3486.

33. Chen Q, Hu Y, Fang Z, Ye M, Li J, Zhang S, et al. Elevated levels of oxidative nucleic acid modification markers in urine from gastric cancer patients: quantitative analysis by ultra performance liquid chromatography-tandem mass spectrometry. Front Chem 2020;8:606495.

34. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0—the human metabolome database in 2013. Nucleic Acids Res 2013;41:D801-D807.

35. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008;455:1054-1056.

36. Zhang T, Watson DG, Wang L, Abbas M, Murdoch L, Bashford L, et al. Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS One 2013;8:e65880.

37. Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst (Lond) 2012;137:293-300.

38. Huang R, Shen K, He Q, Hu Y, Sun C, Guo C, et al. Metabolic profiling of urinary chiral amino-containing biomarkers for gastric cancer using a sensitive chiral chlorine-labeled probe by HPLC-MS/MS. J Proteome Res 2021;20:3952-3962.

39. Chen Y, Zhang J, Guo L, Liu L, Wen J, Xu L, et al. A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis. Oncotarget 2016;7:87496-87510.

40. Chan AW, Mercier P, Schiller D, Bailey R, Robbins S, Eurich DT, et al. (1)H-NMR urinary metabolic profiling for diagnosis of gastric cancer. Br J Cancer 2016;114:59-62.

41. Jung I, Jung Y, Bang EJ, Cho SI, Jang YJ, Kwak JM, et al. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolic profiling. Ann Surg Oncol 2014;21 Suppl 4:S736-S742.

42. Chen JL, Fan J, Lu XJ. CE-MS based on moving reaction boundary method for urinary metabolic analysis of gastric cancer patients. Electrophoresis 2014;35:1032-1039.
43. Kwon HN, Lee H, Park JW, Kim YH, Park S, Kim JJ. Screening for early gastric cancer using a noninvasive urine metabolomics approach. Cancers (Basel) 2020;12:2904.

44. Lyu J, Li H, Yin D, Zhao M, Sun Q, Guo M. Analysis of eight bile acids in urine of gastric cancer patients based on covalent organic framework enrichment coupled with liquid chromatography-tandem mass spectrometry. J Chromatogr A 2021;1:653:462422.

45. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-383.

46. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016;30:836-848.

47. Naito Y, Yoshioka Y, Yamamoto Y, Ochiya T. How cancer cells dictate their microenvironment: present roles of extracellular vesicles. Cell Mol Life Sci 2017;74:697-713.

48. Huang T, Song C, Zheng L, Xia L, Li Y, Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol Cancer 2019;18:62.

49. Park JY, Kang CS, Seo HC, Shin JC, Kym SM, Park YS, et al. Bacteria-derived extracellular vesicles in urine as a novel biomarker for gastric cancer: integration of liquid biopsy and metagenome analysis. Cancers (Basel) 2021;13:4687.

50. Trams EG, Lauter CJ, Salem N Jr, Heine U. Exfoliation of membrane ecto-enzymes in the form of microvesicles. Biochim Biophys Acta 1981;645:63-70.

51. Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, et al. Mechanisms of nuclear content loading to exosomes. Sci Adv 2019;5:eaax8849.

52. Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 2019;18:75.

53. Qian X, Xie F, Wei H, Cui D. Identification of key circulating exosomal microRNAs in gastric cancer. Front Oncol 2021;11:693360.

54. Dong X, Wang G, Zhang G, Ni Z, Luo J, Cui J, et al. The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. Diagn Pathol 2013;8:45.

55. Hong CS, Cui J, Ni Z, Su Y, Puett D, Li F, et al. A computational method for prediction of excretory proteins and application to identification of gastric cancer markers in urine. PLoS One 2011;6:e16875.

56. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011;278:28-45.

57. Herrera C, Escalante T, Rucavado A, Fox JW, Gutiérrez JM. Metalloproteinases in disease: identification of biomarkers of tissue damage through proteomics. Expert Rev Proteomics 2018;15:967-982.

58. Siddhartha R, Garg M. Molecular and clinical insights of matrix metalloproteinases into cancer spread and potential therapeutic interventions. Toxicol Appl Pharmacol 2021;426:115593.

59. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-573.

60. Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, Rathinavelu A. Matrix metalloproteinases: a challenging paradigm of cancer management. Semin Cancer Biol 2019;56:100-115.

61. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-622.
62. Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila) 2015;8:240-248.

PUBMED | CROSSREF

63. Albalat A, Mischak H, Mullen W. Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics 2011;8:615-629.

PUBMED | CROSSREF

64. Shao C, Wang Y, Gao Y. Applications of urinary proteomics in biomarker discovery. Sci China Life Sci 2011;54:409-417.

PUBMED | CROSSREF

65. Shimura T, Dayde D, Wang H, Okuda Y, Iwasaki H, Ebi M, et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer 2020;123:1656-1664.

PUBMED | CROSSREF

66. Harpole M, Davis J, Espina V. Current state of the art for enhancing urine biomarker discovery. Expert Rev Proteomics 2016;13:609-626.

PUBMED | CROSSREF

67. Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev Proteomics 2015;12:623-636.

PUBMED | CROSSREF